Ignite Creation Date:
2025-12-24 @ 6:50 PM
Ignite Modification Date:
2026-01-01 @ 4:07 PM
Study NCT ID:
NCT00525057
Status:
COMPLETED
Last Update Posted:
2021-01-22
First Post:
2007-09-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Dalteparin in Preventing DVT in Participants With Cancer
Sponsor:
M.D. Anderson Cancer Center
Organization:
Study Overview
Official Title:
DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.
Detailed Description:
PRIMARY OBJECTIVES:
I. To determine the safety of dalteparin as prophylaxis against deep venous thrombosis (DVT) in orthopedic oncology patients.
II. To determine whether there are significantly increased bleeding complications at the surgical site after major oncologic operations in the lower extremity.
OUTLINE:
Participants receive dalteparin subcutaneously (SC) once daily (QD) starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
I. To determine the safety of dalteparin as prophylaxis against deep venous thrombosis (DVT) in orthopedic oncology patients.
II. To determine whether there are significantly increased bleeding complications at the surgical site after major oncologic operations in the lower extremity.
OUTLINE:
Participants receive dalteparin subcutaneously (SC) once daily (QD) starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: